Welcome and Introduction (ID 4868)
Is a one size fits all approach still appropriate for NSCLS with an EGFR mutation, are all mutations equal? (ID 4869)
Scientific rationale for dual inhibition of VEGF and EGFR (ID 4870)
Identifying the clinical and disease characteristics of the high risk patient, what is the science telling us? (ID 4871)
Case study from the clinic – Potential patient profile and include sequencing and discuss with panel (ID 4872)
Panel discussion and Q&A (ID 4873)
Symposium closing remarks (ID 4874)
